So many companies to make real money shorting, but yet the fools chose stay with ACHN don't they see the gains ahead for this wealthy company in the near future. Oh well to bad for them, longs will profit.
What's the problem shorty worried that you'll be losing some money.
With J & J investment at 12.25 a share will have no problem rising over that price. The good news with the tests being performed now is the time to accumulate as many shares as possible.
Can Achillion Pharmaceuticals (ACHN) Run Higher on Strong Earnings Estimate Revisions?
Zacks By Zacks Equity Research
1 hour ago
Can Ciber (CBR) Run Higher on Strong Earnings Estimate Revisions? Zacks
Why JA Solar Holdings (JASO) Could Be Positioned for a Surge? Zacks
Why TETRA Technologies (TTI) Could Be Positioned for a Surge? Zacks
Why Ceragon Networks (CRNT) Could Be Positioned for a Surge? Zacks
Surging Earnings Estimates Signal Good News for Genesis Energy (GEL) Zacks
Achillion Pharmaceuticals, Inc. (ACHN) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ACHN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Achillion Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for ACHN
Achillion Pharmaceuticals, Inc …
Can Achillion Pharmaceuticals (ACHN) Run Higher on Strong Earnings Estimate Revisions? Zacks 1 hr 6 mins ago
Does Achillion's 13% Slump in August Make It a Bargain? Motley Fool q 1 day 2 hrs ago
In the past 30 days, 2 estimates have gone higher for Achillion Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 17 cents a share 30 days ago, to a loss of 4 cents today.
Current Year Estimates for ACHN
Meanwhile, Achillion Pharmaceuticals’ current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to no downward revision. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 75 cents per share 30 days ago to a loss of 53 cents per share today.
The stock has also started to move higher lately, adding nearly 10% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
Forget what the shorts are babbling, they will lose.